The Institute For Systems Biology Places A Third Order For Sequencing Services With Complete Genomics, Includes 615 Genomes

"We are proud that leading organizations such as ISB continue to rely on our high-quality and high-throughput sequencing services to conduct large-scale disease studies," said Dr. Clifford Reid, Complete Genomics chairman, president and CEO. "In 2011, we anticipate that many more researchers will look to complete human genome sequencing to help with their studies of disease, and we look forward to working with the research community to continue to provide accurate, consistent and research-ready data. We currently have the ability to sequence and analyze more than 400 complete human genomes per month, and expect this capacity to increase between two- and threefold in 2011."

About the Institute for Systems Biology

The Institute for Systems Biology (ISB) is an internationally renowned, non-profit research institute headquartered in Seattle and dedicated to the study and application of systems biology. Founded in 2000, ISB was established to unravel the mysteries of complex biological systems and to identify strategies for predicting and preventing human diseases such as cancer, diabetes and AIDS. ISB's systems approach integrates biology, computation and technological development, enabling scientists to analyze all elements in a biological system rather than one gene or protein at a time. The Institute has grown to 14 faculty members and more than 250 staff members; has an annual budget of more than $35 million; and an extensive network of academic and industrial partners. For more information about ISB, visit http://www.systemsbiology.org.

About Complete Genomics

Complete Genomics is a life sciences company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics' proprietary human genome sequencing technology with our advanced informatics and data management software. We offer this solution as an innovative, end-to-end, outsourced service, CGA™ Service, and provide customers with data that is immediately ready to be used for genome-based research. Additional information can be found at http://www.completegenomics.com .

The Complete Genomics logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8216

Forward Looking Statements

Certain statements in this press release, including statements relating to our expected monthly genome sequencing capacity, are forward looking statements that are subject to risks and uncertainties. Readers are cautioned that these forward looking statements are based on management's current expectations, and actual results may differ materially from those projected. The following factors, without limitation, could cause actual results to differ materially from those in the forward looking statements: our limited operating history, delays in production due to technical issues and our inability to increase yield. More information on potential factors that could affect our monthly genome sequencing capacity is included in our Securities and Exchange Commission filings and reports, including the risks identified under the section captioned "Risk Factors" in our Quarterly Report on Form 10-Q filed on December 22, 2010. We disclaim any obligation to update information contained in these forward looking statements, whether as a result of new information, future events or otherwise.

« First ‹ Previous 1 2 3 Next › Last »